Jonathan Rachman is a Senior Research Fellow at the Oxford Health Alliance as well as at Harris Manchester College.
His research interests are in the field of Type 2 diabetes. He is collaborating with colleagues at The Oxford Health Alliance and more broadly in the academic and clinical community to create a blueprint for, and then implement, comprehensive, fully joined-up diabetes care in Oxfordshire, including community-based interventions for tackling the obesogenic environment.
Jonathan is a medical graduate of the University of Cape Town. His postgraduate career has focused on the treatment of Type 2 diabetes, an abiding interest catalyzed by his research into potential new pharmacological treatments for Type 2 diabetes, leading to his DPhil, at the University of Oxford. He has 14 years’ drug development experience in the pharmaceutical industry, with stints at Pfizer and Eli Lilly, most recently heading the Oxford-based Type 2 diabetes subsidiary of OSI Pharmaceuticals.